Stocktoria
Mereo BioPharma Group plc MREO
Mereo BioPharma Group plc (MREO) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $500,000 at a -8375.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MREO | Mereo BioPharma Group plc | 3/9 | — | — | — |
| QUCY | Quantum Cyber N.V. | 3/9 | — | — | — |
| SLN | Silence Therapeutics plc | 1/9 | -12.42 | — | -98.7% |
| SCNX | Scienture Holdings, Inc. | 4/9 | -0.88 | — | — |
| VYNE | VYNE Therapeutics Inc. | 2/9 | — | — | — |
| ELAB | PMGC Holdings Inc. | 2/9 | — | — | — |
| MNOV | MEDICINOVA INC | 1/9 | -18.54 | — | — |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
FAQ
Is MREO financially healthy?
Mereo BioPharma Group plc's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does MREO pay a dividend?
No, Mereo BioPharma Group plc does not currently pay a dividend.
How profitable is MREO?
In FY2025, Mereo BioPharma Group plc had a net margin of -8375.6% and a return on equity of -102.4%.
What is the analyst price target for MREO?
The average Wall-Street price target for Mereo BioPharma Group plc is $1.71, about 465.1% above the recent price, from 6 analysts.
Is MREO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Mereo BioPharma Group plc: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.